Reviva Pharmaceuticals Holdings, Inc. (RVPH)
0.3256
-0.26
(-44.81%)
USD |
NASDAQ |
Dec 23, 16:00
0.3152
-0.01
(-3.19%)
After-Hours: 18:31
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 37.46M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -55.97% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 8.234 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.76% |
Profile
| Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA. |
| URL | http://www.revivapharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 30, 2026 (est.) |
| Last Earnings Release | Nov. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA. |
| URL | http://www.revivapharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 30, 2026 (est.) |
| Last Earnings Release | Nov. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |